Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03371459 · ClinicalTrials.gov registry record · Phase 2
Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma
A Phase 2 study of Asthma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 5
- Study locations
NCT03371459 is a Phase 2 study of Asthma that has completed, run by AstraZeneca. The registered enrollment target is 46 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT03371459, a Phase 2 study of Asthma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a randomized, cumulative dose, open-label, 2-period crossover, multi-center study to assess the safety, efficacy, PK, and extrapulmonary PD of cumulative doses of AS MDI compared to cumulative doses of Proventil as an active control in subjects with mild to moderate asthma
Conditions Studied
Interventions
- DRUG AS MDI
- DRUG Proventil
Study Locations (5)
Florida
- Research Site - Winter Park
Massachusetts
- Research Site - North Dartmouth
Missouri
- Research Site - St Louis
North Carolina
- Research Site - Raleigh
Oregon
- Research Site - Medford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2017-12-29 |
| Est. Completion | 2018-03-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03371459
The ClinicalTrials.gov registry entry for NCT03371459 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which AS MDI is the first listed.
NCT03371459 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Florida, Massachusetts, Missouri.
Frequently Asked Questions
What is clinical trial NCT03371459 about?
NCT03371459 is a clinical study titled "Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma". This is a randomized, cumulative dose, open-label, 2-period crossover, multi-center study to assess the safety, efficacy, PK, and extrapulmonary PD of cumulative doses of AS MDI compared to cumulative doses of Proventil as an active control in subjects with mild to moderate asthma
What is the current status of trial NCT03371459?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2017-12-29. Estimated completion is 2018-03-26.
What conditions does trial NCT03371459 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT03371459?
The interventions under investigation include: AS MDI (DRUG), Proventil (DRUG).
Who is sponsoring clinical trial NCT03371459?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03371459 being conducted?
This trial has 5 study locations across Florida, Massachusetts, Missouri, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.